HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance
- 1 September 2015
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 5 (9), 944-959
- https://doi.org/10.1158/2159-8290.cd-15-0090
Abstract
Why breast cancers become resistant to tamoxifen despite continued expression of the estrogen receptor-α (ERα) and what factors are responsible for high HER2 expression in these tumors remains an enigma. HOXB7 chromatin immunoprecipitation analysis followed by validation showed that HOXB7 physically interacts with ERα, and that the HOXB7–ERα complex enhances transcription of many ERα target genes, including HER2. Investigating strategies for controlling HOXB7, our studies revealed that MYC, stabilized via phosphorylation mediated by EGFR–HER2 signaling, inhibits transcription of miR-196a, a HOXB7 repressor. This leads to increased expression of HOXB7, ER target genes, and HER2. Repressing MYC using small-molecule inhibitors reverses these events and causes regression of breast cancer xenografts. The MYC–HOXB7–HER2 signaling pathway is eminently targetable in endocrine-resistant breast cancer. Significance: HOXB7 acts as an ERα cofactor regulating a myriad of ER target genes, including HER2, in tamoxifen-resistant breast cancer. HOXB7 expression is controlled by MYC via transcriptional regulation of the HOXB7 repressor miR-196a; consequently, antagonists of MYC cause reversal of selective ER modulator resistance both in vitro and in vivo. Cancer Discov; 5(9); 944–59. ©2015 AACR. See related commentary by Heideman et al., p. 909. This article is highlighted in the In This Issue feature, p. 893Keywords
Other Versions
This publication has 68 references indexed in Scilit:
- Targeting of the MYCN Protein with Small Molecule c-MYC InhibitorsPLOS ONE, 2014
- ChIP-PED enhances the analysis of ChIP-seq and ChIP-chip dataBioinformatics, 2013
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerThe New England Journal of Medicine, 2012
- Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cellsCancer Letters, 2011
- Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers - role of estrogen receptor and HER2 reactivationBreast Cancer Research, 2011
- Interaction of Developmental Transcription Factor HOXC11 with Steroid Receptor Coactivator SRC-1 Mediates Resistance to Endocrine Therapy in Breast CancerCancer Research, 2010
- New insights into the functions and regulation of the transcriptional corepressors SMRT and N-CoRCell Division, 2009
- Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifenNature, 2008
- Genome-wide analysis of estrogen receptor binding sitesNature Genetics, 2006
- Multiple Ras-dependent phosphorylation pathways regulate Myc protein stabilityGenes & Development, 2000